Punit Dhillon - 24 Feb 2025 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Executive Officer, Director
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
24 Feb 2025
Transactions value $
$0
Form type
4
Date filed
26 Feb 2025, 17:43
Previous filing
19 Nov 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Stock Option (Right to Buy) Award $0 +250K $0.00 250K 24 Feb 2025 Common Stock 250K $2.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests in equal monthly installments over the one year period beginning February 21, 2025.